Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biological Chemistry

Gene Silencer's Special Delivery

Conjugation improves uptake of short RNAs, silencing of targeted genes

by CELIA HENRY
November 15, 2004 | A version of this story appeared in Volume 82, Issue 46

TROJAN HORSE
[+]Enlarge
Credit: ADAPTED FROM NATURE
In RNAi, short pieces of RNA known as siRNA target the messenger RNA of the gene to be silenced and guide it into the RNA-induced silencing complex (RISC), which cleaves the mRNA and prevents gene expression. In Alnylam's modification, cholesterol is conjugated to the siRNA at the 3' end of the 'sense' strand (blue), allowing it to be delivered systemically. Destruction of the sense strand leaves the antisense strand (red) to bind to the target sequence in mRNA.
Credit: ADAPTED FROM NATURE
In RNAi, short pieces of RNA known as siRNA target the messenger RNA of the gene to be silenced and guide it into the RNA-induced silencing complex (RISC), which cleaves the mRNA and prevents gene expression. In Alnylam's modification, cholesterol is conjugated to the siRNA at the 3' end of the 'sense' strand (blue), allowing it to be delivered systemically. Destruction of the sense strand leaves the antisense strand (red) to bind to the target sequence in mRNA.

RNA INTERFERENCE

Delivery is one of the primary hurdles to developing drugs based on the gene-silencing technique called RNA interference (RNAi). Scientists at Alnylam Pharmaceuticals in Kulmbach, Germany, and Cambridge, Mass., now show that chemical modification can assist delivery of the short interfering RNAs (siRNAs) used in RNAi [Nature, 432, 173 (2004)]. By conjugating the siRNAs to cholesterol, the researchers improved the stability of the siRNAs in blood and mediated their uptake by cells.

The scientists demonstrated the method with apolipoprotein B, a protein involved in the formation of low-density lipoproteins (LDLs, the "bad" cholesterol). They prepared modified siRNAs designed to target the genes for apolipoprotein B. When injected into mice, the cholesterol-conjugated siRNAs were taken up by the liver and other tissues, where they significantly reduced expression of apolipoprotein B, leading to lower levels of blood cholesterol.

Don't expect an RNAi therapeutic to hit doctors' offices too quickly, though. "It will be several years before we can bring the systemic approach into the clinic," says Hans-Peter Vornlocher, vice president for research of Alnylam Europe and lead author on the study.

In a commentary, John J. Rossi, of Beckman Research Institute of the City of Hope, in Duarte, Calif., writes: "It remains to be seen whether the cholesterol-conjugate approach can be used to silence other disease-related genes in animal models. If so, it should revolutionize the use of RNAi."

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.